Temperature Control After Cardiac Arrest: A Narrative Review
Abstract Cardiac arrest (CA) is a critical public health issue affecting more than half a million Americans annually. The main determinant of outcome post-CA is hypoxic–ischemic brain injury (HIBI), and temperature control is currently the only evidence-based, guideline-recommended intervention targeting secondary brain injury. Temperature control is a key component of a post-CA care bundle; however, conflicting evidence challenges its wide implementation across the vastly heterogeneous population of CA survivors. Here, we critically appraise the available literature on temperature control in HIBI, detail how the evidence has been integrated into clinical practice, and highlight the complications associated with its use and the timing of neuroprognostication after CA. Future clinical trials evaluating different temperature targets, rates of rewarming, duration of cooling, and identifying which patient phenotype benefits from different temperature control methods are needed to address these prevailing knowledge gaps..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Advances in therapy - 40(2023), 5 vom: 25. März, Seite 2097-2115 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fernandez Hernandez, Samantha [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Cardiac arrest |
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1007/s12325-023-02494-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2134684151 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2134684151 | ||
| 003 | DE-627 | ||
| 005 | 20230510163056.0 | ||
| 007 | tu | ||
| 008 | 230510s2023 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12325-023-02494-1 |2 doi | |
| 035 | |a (DE-627)OLC2134684151 | ||
| 035 | |a (DE-He213)s12325-023-02494-1-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.40$jPharmazie$jPharmazeutika |2 bkl | ||
| 100 | 1 | |a Fernandez Hernandez, Samantha |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Temperature Control After Cardiac Arrest: A Narrative Review |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Abstract Cardiac arrest (CA) is a critical public health issue affecting more than half a million Americans annually. The main determinant of outcome post-CA is hypoxic–ischemic brain injury (HIBI), and temperature control is currently the only evidence-based, guideline-recommended intervention targeting secondary brain injury. Temperature control is a key component of a post-CA care bundle; however, conflicting evidence challenges its wide implementation across the vastly heterogeneous population of CA survivors. Here, we critically appraise the available literature on temperature control in HIBI, detail how the evidence has been integrated into clinical practice, and highlight the complications associated with its use and the timing of neuroprognostication after CA. Future clinical trials evaluating different temperature targets, rates of rewarming, duration of cooling, and identifying which patient phenotype benefits from different temperature control methods are needed to address these prevailing knowledge gaps. | ||
| 650 | 4 | |a Cardiac arrest | |
| 650 | 4 | |a Targeted temperature management | |
| 650 | 4 | |a Post-cardiac arrest syndrome | |
| 650 | 4 | |a Heart arrest | |
| 650 | 4 | |a Hypothermia | |
| 650 | 4 | |a Temperature control | |
| 700 | 1 | |a Barlow, Brooke |4 aut | |
| 700 | 1 | |a Pertsovskaya, Vera |4 aut | |
| 700 | 1 | |a Maciel, Carolina B. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advances in therapy |d Springer Healthcare, 1984 |g 40(2023), 5 vom: 25. März, Seite 2097-2115 |w (DE-627)168085585 |w (DE-600)632651-1 |w (DE-576)482252200 |x 0741-238X |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2023 |g number:5 |g day:25 |g month:03 |g pages:2097-2115 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s12325-023-02494-1 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 936 | b | k | |a 44.40$jPharmazie$jPharmazeutika |q VZ |0 106423304 |0 (DE-625)106423304 |
| 951 | |a AR | ||
| 952 | |d 40 |j 2023 |e 5 |b 25 |c 03 |h 2097-2115 | ||